For weight loss, Klinic more commonly prescribes Zepbound, which aligns with FDA approval for that purpose and is likelier to secure coverage
Now, two new late-phase clinical trials, sponsored by Eli Lilly and Company, suggest that transitioning from high dose injectable weight loss medications to either a daily pill or a lower maintenance dose can help people living with obesity to keep off most of the weight they have already lost The results of the ATTAIN-MAINTAIN and SURMOUNT-MAINTAIN trials were presented at the European Congress on Obesity and published in Previous research suggests that 1 year after stopping weight loss medication, people may regain, on average, 60% of their lost weight
A single dose of recently expired semaglutide is unlikely to cause serious harm
The recommended starting dosage of SOLIQUA 100/33 is 30 units (30 units insulin glargine and 10 mcg lixisenatide) given subcutaneously once daily
While you may still lose weight, it is likely to be slower and less consistent than the results seen in clinical studies